Skip to content
OpenCapital
Get started

IQVIA IQV Research & Development Solutions — Business combinations

Other segment segments

Commercial Solutions
$26M—

Similar metrics at other companies

Aclaris Therapeutics logo
ACRSIn Process Research And Development Expense
$21.73M+1,211%
Harmony Biosciences Holdings, Inc. logo
HRMYIn Process Research And Development Acquired
$32M—
Mirum Pharmaceuticals, Inc. logo
MIRMReportable Segment — Acquired in-process research and development
$726.3M+14,426%
Corvex logo
MOVESegment Reporting — Research And Development Expense
$1.2M—
Tandem Diabetes Care logo
TNDMAcquired in-process research and development expenses
$0-100%
BioCryst Pharmaceuticals logo
BCRXReportable Segment — Acquired in-process research and development
$697.76M—

Other financials

Income statement

See full
Revenue$4.2B+8.4%
Gross profit$1.4B+4.4%
Operating income$514.0M+3.6%
Net income$274.0M+10.0%
EPS (diluted)$1.61+15.0%

Balance sheet

See full
Cash & equivalents$1.9B+11.9%
Total debt$16.1B+10.7%
Total equity$6.2B+4.1%
Total assets$29.7B+8.6%

Cash flow

See full
Operating cash flow$618.0M+8.8%
CapEx$127.0M-10.6%
Free cash flow$491.0M+15.3%

Valuation

See full
Market cap$31.9B+17.5%
Enterprise value$46.02B+12.8%
P/E23×+1.1×
P/S1.9×+0.2×

Profitability

See full
Gross margin33%-1.7pp
Operating margin13.2%-0.9pp
Net margin8.3%-0.3pp
FCF margin12.7%-1.2pp

Returns & leverage

See full
Return on equity22.7%+1.1pp
Debt / equity2.6×+0.2×
Current ratio0.7×-0.1×

Where this comes from

Reported directly by IQVIA in its filing.

Tagged under the XBRL concept us-gaap:GoodwillAcquiredDuringPeriod.

The official record: IQVIA’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about IQVIA's research & development solutions — business combinations.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IQVIA's research & development solutions — business combinations?
IQVIA (IQV) reported research & development solutions — business combinations of $4M in Q1 2026.
What is the long-term trend for IQVIA's research & development solutions — business combinations?
Over 3 years (2021 to 2025), IQVIA's research & development solutions — business combinations has grown at a 35.9% compound annual growth rate (CAGR), from $160M to $402M.
What does research & development solutions — business combinations mean?
Captures the financial impact of integrating newly acquired entities into the research and development solutions segment. This metric tracks the capital deployed for inorganic expansion and the immediate financial footprint of these strategic mergers and acquisitions.